327 related articles for article (PubMed ID: 28912274)
21. Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes.
Poepsel S; Kasinath V; Nogales E
Nat Struct Mol Biol; 2018 Feb; 25(2):154-162. PubMed ID: 29379173
[TBL] [Abstract][Full Text] [Related]
22. EZH2: biology, disease, and structure-based drug discovery.
Tan JZ; Yan Y; Wang XX; Jiang Y; Xu HE
Acta Pharmacol Sin; 2014 Feb; 35(2):161-74. PubMed ID: 24362326
[TBL] [Abstract][Full Text] [Related]
23. Structural insights into the interactions of Polycomb Repressive Complex 2 with chromatin.
Iragavarapu AG; Yao L; Kasinath V
Biochem Soc Trans; 2021 Dec; 49(6):2639-2653. PubMed ID: 34747969
[TBL] [Abstract][Full Text] [Related]
24. Dominant alleles identify SET domain residues required for histone methyltransferase of Polycomb repressive complex 2.
Joshi P; Carrington EA; Wang L; Ketel CS; Miller EL; Jones RS; Simon JA
J Biol Chem; 2008 Oct; 283(41):27757-27766. PubMed ID: 18693240
[TBL] [Abstract][Full Text] [Related]
25. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
[TBL] [Abstract][Full Text] [Related]
26. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
27. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
28. Structural analysis of an active fungal PRC2.
Jiao L; Liu X
Nucleus; 2016 May; 7(3):284-91. PubMed ID: 27187637
[TBL] [Abstract][Full Text] [Related]
29. Recent Structural Insights into Polycomb Repressive Complex 2 Regulation and Substrate Binding.
Kasinath V; Poepsel S; Nogales E
Biochemistry; 2019 Feb; 58(5):346-354. PubMed ID: 30451485
[TBL] [Abstract][Full Text] [Related]
30. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
31. Strategy for "detoxification" of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2.
Brown ZZ; Müller MM; Jain SU; Allis CD; Lewis PW; Muir TW
J Am Chem Soc; 2014 Oct; 136(39):13498-501. PubMed ID: 25180930
[TBL] [Abstract][Full Text] [Related]
32. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
33. Role of histone H3 lysine 27 methylation in Polycomb-group silencing.
Cao R; Wang L; Wang H; Xia L; Erdjument-Bromage H; Tempst P; Jones RS; Zhang Y
Science; 2002 Nov; 298(5595):1039-43. PubMed ID: 12351676
[TBL] [Abstract][Full Text] [Related]
34. Molecular architecture of human polycomb repressive complex 2.
Ciferri C; Lander GC; Maiolica A; Herzog F; Aebersold R; Nogales E
Elife; 2012 Oct; 1():e00005. PubMed ID: 23110252
[TBL] [Abstract][Full Text] [Related]
35. The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing.
Mozzetta C; Pontis J; Fritsch L; Robin P; Portoso M; Proux C; Margueron R; Ait-Si-Ali S
Mol Cell; 2014 Jan; 53(2):277-89. PubMed ID: 24389103
[TBL] [Abstract][Full Text] [Related]
36. Targeting of cancer stem cells by inhibitors of DNA and histone methylation.
Momparler RL; Côté S
Expert Opin Investig Drugs; 2015; 24(8):1031-43. PubMed ID: 26004134
[TBL] [Abstract][Full Text] [Related]
37. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Catalano R; Rocca R; Juli G; Costa G; Maruca A; Artese A; Caracciolo D; Tagliaferri P; Alcaro S; Tassone P; Amodio N
Eur J Med Chem; 2019 Dec; 183():111715. PubMed ID: 31550663
[TBL] [Abstract][Full Text] [Related]
38. PRC2 directly methylates GATA4 and represses its transcriptional activity.
He A; Shen X; Ma Q; Cao J; von Gise A; Zhou P; Wang G; Marquez VE; Orkin SH; Pu WT
Genes Dev; 2012 Jan; 26(1):37-42. PubMed ID: 22215809
[TBL] [Abstract][Full Text] [Related]
39. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2.
Huang D; Tian S; Qi Y; Zhang JZH
Chemphyschem; 2020 Feb; 21(3):263-271. PubMed ID: 31816138
[TBL] [Abstract][Full Text] [Related]
40. Single-molecule and in silico dissection of the interaction between Polycomb repressive complex 2 and chromatin.
Leicher R; Ge EJ; Lin X; Reynolds MJ; Xie W; Walz T; Zhang B; Muir TW; Liu S
Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30465-30475. PubMed ID: 33208532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
